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Early, Goal-Directed Resuscitation for Septic Shock
To the Editor: The Protocolised Management 
in Sepsis (ProMISe) trial (April 2 issue)1 com-
pletes a trio of studies1-3 that question the further 
application of early, goal-directed therapy (EGDT) 
as suggested by Rivers et al.4 In particular, these 
trials consistently show no survival benefit with 
regard to the mandated use of central venous 
oxygen saturation (ScvO2) monitoring. However, 
it remains questionable whether the results of 
the three trials support this claim. According to 
the EGDT protocol, an ScvO2 value of less than 
70% is a trigger for hemodynamic intervention. 
Unlike in the study by Rivers et al., the reported 
mean values at baseline in all three trials do not 
require any intervention. Whether the reported 
survival benefit in the study by Rivers et al. is 
based on the treatment of patients with initially 
extremely low ScvO2 values and determines the 
targeted patient population that benefits from 
EGDT remains, therefore, unanswered. Pope et al.5 
reported increased mortality when ScvO2 values 
were initially low (<70%) or high (>80%). Unless 
subgroup analyses and further studies that focus 
on these high-risk patients do not rule out a sur-
vival benefit, the final conclusion of the three 
trials cannot be supported.
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To the Editor: The ProMISe trial investigators 
report that EGDT did not reduce 90-day mortal-
ity among patients with early septic shock. Fluid 
therapy is crucial in EGDT. By 72 hours, approxi-
mately 40% of the study patients had  received a 
median of 1.0 liter of intravenous colloids, and 
98% of the patients had received a median of 4.9 
liters of intravenous crystalloids (Table S7 in the 
Supplementary Appendix of the article, available 
with the full text of the article at NEJM.org). The 
values for the interquartile range indicate that 
individual patients had received considerably 
larger amounts. Similar amounts of fluids in the 
treatment of early septic shock have been shown 
to increase mean serum chloride concentrations 
from 100 mmol per liter initially to 106 to 108 
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mmol per liter during the first 72 hours,1 probably 
related to the use of hyperchloremic solutions. 
Such solutions are well known to be associated 
with numerous adverse outcomes.2,3 Red-cell 
transfusion is also associated with worse out-
comes, including those in critically ill patients.4 
Because the use of hyperchloremic solutions and 
blood transfusions might have obscured poten-
tial treatment effects, information regarding types 
of fluids, serum chloride concentrations, and the 
reason for the significantly higher frequency of 
red-cell transfusions in the EGDT group than in 
the usual-care group is required.
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University Hospital Freiburg 
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To the Editor: The ProMISe trial, the Austral-
asian Resuscitation in Sepsis Evaluation (ARISE) 
trial, and the Protocolized Care for Early Septic 
Shock (ProCESS) trial suggest no additional ben-
efit from hemodynamic management with strict 
EGDT, characterizing EGDT only as a hemody-
namic study. In addition to hemodynamic moni-
toring from the EGDT component, the Surviving 
Sepsis Campaign (SSC) guidelines1 include early 
detection of high-risk patients with the use of the 
criteria of the systemic inflammatory response 
syndrome, the shock index (ratio of heart rate to 
systolic blood pressure), and measurement of se-
rum lactate levels. EGDT has played a central role 
in the development of current tenets of shock 
management. In the triad of randomized, con-
trolled trials, each component of EGDT was ap-
plied in all groups except monitoring of central 
venous pressure and ScvO2, and they were pro-
vided in more than 50% of the participants in the 
usual-care groups. Mortality decreased in both 
control and intervention groups by more than 
50% — a greater degree than in previous trials. 
These results strongly support the pivotal role of 
the SSC guidelines that include EGDT.1-3 Although 
these trials reveal that monitoring of central ve-
nous pressure is not mandatory, they show no 
harm in EGDT and certainly do not suggest that 
other aspects of the guidelines be called into 
question. We are concerned that the conclusions 
promulgated by the triad of trials will be misinter-
preted and will cast doubt on the importance of 
SSC protocols for sepsis detection and treatment.
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The authors reply: Auinger and Maggiorini 
suggest that the ProCESS,1 ARISE,2 and ProMISe 
trials reported mean ScvO2 values at baseline that 
are considerably higher than those in both the 
EGDT group and the usual-care group in the 
study by Rivers et al.3 The values to which they 
refer for the EGDT groups in the three trials, 
however, are not baseline values and are typically 
from at least 1 hour postrandomization (after in-
sertion of the catheter with ScvO2 monitoring 
capability). The values in the study by Rivers et al. 
are prerandomization (all patients received cathe-
ters with ScvO2 monitoring capability before 
randomization in this study), and, therefore, 
the comparison is not valid. Subgroup analyses 
of high-risk patients in the three multicenter 
trials, using illness-severity scores, serum lactate 
 concentrations, or both as proxies for baseline 
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ScvO2 (because ScvO2 data were not available for 
the usual-care groups), showed no evidence of 
benefit.
We agree with Priebe that administration of 
intravenous isotonic saline solutions can cause 
hyperchloremia and acidosis. In the ProMISe trial, 
although we did not record the type of crystal-
loid administered or the serum chloride level, the 
volume of crystalloid administered by 72 hours 
after randomization was similar in the EGDT 
and usual-care groups, and it is likely that, on 
average, the fluids used were the same in the 
two groups. With respect to red-cell transfusions, 
the evidence base is conflicting, with more recent 
data4,5 indicating no evidence of harm caused by 
transfusions.
Manaktala and Claypool are concerned about 
misinterpretation of the results of the ProCESS, 
ARISE, and ProMISe trials. With interpretation 
in mind, we stated in the Conclusions section of 
the abstract of our article that “in patients with 
septic shock who were identified early and re-
ceived intravenous antibiotics and adequate fluid 
resuscitation, hemodynamic management accord-
ing to a strict EGDT protocol did not lead to an 
improvement in outcome.”
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Intensive Care National Audit and Research Centre 
London, United Kingdom
Timothy J. Coats, M.D.
University of Leicester 
Leicester, United Kingdom
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. The ProCESS Investigators. A randomized trial of protocol-
based care for early septic shock. N Engl J Med 2014;370:1683-93.
2. The ARISE Investigators and the ANZICS Clinical Trials 
Group. Goal-directed resuscitation for patients with early septic 
shock. N Engl J Med 2014;371:1496-506.
3. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed 
therapy in the treatment of severe sepsis and septic shock. N Engl 
J Med 2001;345:1368-77.
4. Lacroix J, Hébert PC, Fergusson DA, et al. Age of transfused 
blood in critically ill adults. N Engl J Med 2015;372:1410-8.
5. Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive 
transfusion after cardiac surgery. N Engl J Med 2015;372:997-1008.
DOI: 10.1056/NEJMc1506514
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
To the Editor: Sequist et al. (April 30 issue)1 
report that rociletinib can overcome the resistance 
to epidermal growth factor receptor (EGFR) tyro-
sine kinase inhibitors in patients with non–small-
cell lung cancer (NSCLC) harboring the EGFR 
T790M resistance mutation. Rociletinib treatment 
was associated with significantly longer progres-
sion-free survival among such patients than 
among patients not harboring these mutations. 
We noted that of the 92 study patients who re-
ceived therapeutic doses of rociletinib, 35 (38%) 
also received glucose-lowering therapy (typically 
metformin) to treat hyperglycemia.
Metformin, an antidiabetic drug, has been 
shown to exert anticancer activity. Lin et al. re-
ported that metformin administration is associ-
ated with improved survival among patients with 
stage IV NSCLC with diabetes.2 Our study showed 
that metformin sensitizes NSCLC cells that are 
resistant to EGFR tyrosine kinase inhibitors.3 
Furthermore, metformin suppresses the expres-
sion of the main detoxification enzyme, cyto-
chrome P-450 3A4.4 Therefore, it could theoreti-
cally elevate plasma concentrations of rociletinib. 
These effects raise the possibility that metfor-
min may have affected the results of the study 
by Sequist et al. I would like to know whether 
the patients who received rociletinib and metfor-
min had better outcomes than those who received 
rociletinib only.
Yong He, Ph.D., M.D.
Daping Hospital of the Third Military Medical University 
Chongqing, China 
heyong8998@126.com
No potential conflict of interest relevant to this letter was re-
ported.
1. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-
mutated non–small-cell lung cancer. N Engl J Med 2015;372: 
1700-9.
2. Lin JJ, Gallagher EJ, Sigel K, et al. Survival of patients with 
stage IV lung cancer with diabetes treated with metformin. Am 
J Respir Crit Care Med 2015;191:448-54.
3. Li L, Han R, Xiao H, et al. Metformin sensitizes EGFR-TKI-
resistant human lung cancer cells in vitro and in vivo through 
inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 
2014;20:2714-26.
4. Krausova L, Stejskalova L, Wang H, et al. Metformin sup-
presses pregnane X receptor (PXR)-regulated transactivation of 
CYP3A4 gene. Biochem Pharmacol 2011;82:1771-80.
DOI: 10.1056/NEJMc1506831
The authors reply: We agree that some evidence 
suggests that metformin has intrinsic anticancer 
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